Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School.
Circ Res. 2023 Jun 9;132(12):1663-1673. doi: 10.1161/CIRCRESAHA.123.322000. Epub 2023 Jun 8.
Cardiometabolic diseases, including cardiovascular disease and diabetes, are major causes of morbidity and mortality worldwide. Despite progress in prevention and treatment, recent trends show a stalling in the reduction of cardiovascular disease morbidity and mortality, paralleled by increasing rates of cardiometabolic disease risk factors in young adults, underscoring the importance of risk assessments in this population. This review highlights the evidence for molecular biomarkers for early risk assessment in young individuals. We examine the utility of traditional biomarkers in young individuals and discuss novel, nontraditional biomarkers specific to pathways contributing to early cardiometabolic disease risk. Additionally, we explore emerging omic technologies and analytical approaches that could enhance risk assessment for cardiometabolic disease.
心血管疾病和糖尿病等心脏代谢疾病是全球发病率和死亡率的主要原因。尽管在预防和治疗方面取得了进展，但最近的趋势显示，心血管疾病发病率和死亡率的下降趋势停滞不前，与此同时，年轻人的心脏代谢疾病风险因素的发生率却在上升，这突显出对这一年龄段人群进行风险评估的重要性。本综述重点介绍了用于年轻人早期风险评估的分子生物标志物的证据。我们检查了传统生物标志物在年轻人中的应用，并讨论了特定于导致早期心脏代谢疾病风险的途径的新型非传统生物标志物。此外，我们还探讨了新兴的组学技术和分析方法，这些方法可能会增强心脏代谢疾病的风险评估。
